Cargando…
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
In patients with nonvalvular atrial fibrillation (AF), the risk of stroke varies considerably according to individual clinical status. The CHA(2)DS(2)-VASc score is better than the CHADS(2) score for identifying truly lower risk patients with AF. With the advent of novel oral anticoagulants (NOACs),...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310986/ https://www.ncbi.nlm.nih.gov/pubmed/25653698 http://dx.doi.org/10.4070/kcj.2015.45.1.9 |
_version_ | 1782354938277396480 |
---|---|
author | Jung, Byung Chun Kim, Nam Ho Nam, Gi Byung Park, Hyung Wook On, Young Keun Lee, Young Soo Lim, Hong Euy Joung, Boyoung Cha, Tae Joon Hwang, Gyo Seung Oh, Seil Kim, June Soo |
author_facet | Jung, Byung Chun Kim, Nam Ho Nam, Gi Byung Park, Hyung Wook On, Young Keun Lee, Young Soo Lim, Hong Euy Joung, Boyoung Cha, Tae Joon Hwang, Gyo Seung Oh, Seil Kim, June Soo |
author_sort | Jung, Byung Chun |
collection | PubMed |
description | In patients with nonvalvular atrial fibrillation (AF), the risk of stroke varies considerably according to individual clinical status. The CHA(2)DS(2)-VASc score is better than the CHADS(2) score for identifying truly lower risk patients with AF. With the advent of novel oral anticoagulants (NOACs), the strategy for antithrombotic therapy has undergone significant changes due to its superior efficacy, safety and convenience compared with warfarin. Furthermore, new aspects of antithrombotic therapy and risk assessment of stroke have been revealed: the efficacy of stroke prevention with aspirin is weak, while the risk of major bleeding is not significantly different from that of oral anticoagulant (OAC) therapy, especially in the elderly. Reflecting these pivotal aspects, previous guidelines have been updated in recent years by overseas societies and associations. The Korean Heart Rhythm Society has summarized the new evidence and updated recommendations for stroke prevention of patients with nonvalvular AF. First of all, antithrombotic therapy must be considered carefully and incorporate the clinical characteristics and circumstances of each individual patient, especially with regards to balancing the benefits of stroke prevention with the risk of bleeding, recommending the CHA(2)DS(2)-VASc score rather than the CHADS(2) score for assessing the risk of stroke, and employing the HAS-BLED score to validate bleeding risk. In patients with truly low risk (lone AF, CHA(2)DS(2)-VASc score of 0), no antithrombotic therapy is recommended, whereas OAC therapy, including warfarin (international normalized ratio 2-3) or NOACs, is recommended for patients with a CHA(2)DS(2)-VASc score ≥2 unless contraindicated. In patients with a CHA(2)DS(2)-VASc score of 1, OAC therapy should be preferentially considered, but depending on bleeding risk or patient preferences, antiplatelet therapy or no therapy could be permitted. |
format | Online Article Text |
id | pubmed-4310986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | The Korean Society of Cardiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-43109862015-02-04 The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society Jung, Byung Chun Kim, Nam Ho Nam, Gi Byung Park, Hyung Wook On, Young Keun Lee, Young Soo Lim, Hong Euy Joung, Boyoung Cha, Tae Joon Hwang, Gyo Seung Oh, Seil Kim, June Soo Korean Circ J Review Article In patients with nonvalvular atrial fibrillation (AF), the risk of stroke varies considerably according to individual clinical status. The CHA(2)DS(2)-VASc score is better than the CHADS(2) score for identifying truly lower risk patients with AF. With the advent of novel oral anticoagulants (NOACs), the strategy for antithrombotic therapy has undergone significant changes due to its superior efficacy, safety and convenience compared with warfarin. Furthermore, new aspects of antithrombotic therapy and risk assessment of stroke have been revealed: the efficacy of stroke prevention with aspirin is weak, while the risk of major bleeding is not significantly different from that of oral anticoagulant (OAC) therapy, especially in the elderly. Reflecting these pivotal aspects, previous guidelines have been updated in recent years by overseas societies and associations. The Korean Heart Rhythm Society has summarized the new evidence and updated recommendations for stroke prevention of patients with nonvalvular AF. First of all, antithrombotic therapy must be considered carefully and incorporate the clinical characteristics and circumstances of each individual patient, especially with regards to balancing the benefits of stroke prevention with the risk of bleeding, recommending the CHA(2)DS(2)-VASc score rather than the CHADS(2) score for assessing the risk of stroke, and employing the HAS-BLED score to validate bleeding risk. In patients with truly low risk (lone AF, CHA(2)DS(2)-VASc score of 0), no antithrombotic therapy is recommended, whereas OAC therapy, including warfarin (international normalized ratio 2-3) or NOACs, is recommended for patients with a CHA(2)DS(2)-VASc score ≥2 unless contraindicated. In patients with a CHA(2)DS(2)-VASc score of 1, OAC therapy should be preferentially considered, but depending on bleeding risk or patient preferences, antiplatelet therapy or no therapy could be permitted. The Korean Society of Cardiology 2015-01 2015-01-26 /pmc/articles/PMC4310986/ /pubmed/25653698 http://dx.doi.org/10.4070/kcj.2015.45.1.9 Text en Copyright © 2015 The Korean Society of Cardiology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Jung, Byung Chun Kim, Nam Ho Nam, Gi Byung Park, Hyung Wook On, Young Keun Lee, Young Soo Lim, Hong Euy Joung, Boyoung Cha, Tae Joon Hwang, Gyo Seung Oh, Seil Kim, June Soo The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society |
title | The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society |
title_full | The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society |
title_fullStr | The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society |
title_full_unstemmed | The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society |
title_short | The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society |
title_sort | korean heart rhythm society's 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: korean heart rhythm society |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310986/ https://www.ncbi.nlm.nih.gov/pubmed/25653698 http://dx.doi.org/10.4070/kcj.2015.45.1.9 |
work_keys_str_mv | AT jungbyungchun thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT kimnamho thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT namgibyung thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT parkhyungwook thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT onyoungkeun thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT leeyoungsoo thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT limhongeuy thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT joungboyoung thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT chataejoon thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT hwanggyoseung thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT ohseil thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT kimjunesoo thekoreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT jungbyungchun koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT kimnamho koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT namgibyung koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT parkhyungwook koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT onyoungkeun koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT leeyoungsoo koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT limhongeuy koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT joungboyoung koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT chataejoon koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT hwanggyoseung koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT ohseil koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety AT kimjunesoo koreanheartrhythmsocietys2014statementonantithrombotictherapyforpatientswithnonvalvularatrialfibrillationkoreanheartrhythmsociety |